We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.08% | 106.00 | 625 | 14:05:21 |
From May 2019 to May 2024
By Matt Grossman
Abbott Laboratories has received approval from the Food and Drug Administration for implantable devices for patients with heart-rhythm disorders, the company said Monday.
The approval covers the company's cardioverter defibrillator and resynchronization-therapy defibrillator devices. The devices include Bluetooth technology and a smartphone app to improve monitoring capability.
The devices are used to reduce the risks of arrythmias and restore the heart's natural beating pattern if the heart's chambers beat out of sync, Abbott said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 06, 2020 07:55 ET (11:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
